Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362548596> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4362548596 abstract "<div><p>Patients with advanced gastroesophageal cancer (mEG) and tumor mutational burden ≥10 mut/Mb (TMB ≥ 10) have more favorable outcomes on immune checkpoint inhibitor (ICPI) monotherapy compared with chemotherapy in subgroup analyses of randomized controlled trials. We sought to evaluate the robustness of these associations in real-world settings where patients and practices are more diverse. A total of 362 2 L and 692 1 L patients, respectively received ICPI (<i>n</i> = 99, 33) or chemotherapy (<i>n</i> = 263, 659) across approximately 280 U.S. academic or community-based cancer clinics March 2014–July 2021. Deidentified data were captured into a real-world clinico-genomic database. All patients underwent Foundation Medicine testing. Time to next treatment (TTNT) and overall survival (OS) comparing ICPI versus chemotherapy were adjusted for treatment assignment imbalances using propensity scores. 2L: TMB ≥ 10 had more favorable TTNT [median 24 vs. 4.1 months; HR: 0.19; 95% confidence interval (CI): 0.09–0.44; <i>P</i> = 0.0001] and OS (median 43.1 vs. 6.2 months; HR: 0.24; 95% CI: 0.011–0.54; <i>P</i> = 0.0005), TMB < 10 did not (<i>P</i> > 0.05). 1L: TMB ≥ 10 had more favorable TTNT (not reached vs. median 4.1 months; HR: 0.13; 95% CI: 0.03–0.48; <i>P</i> = 0.0024) and OS (not reached vs. median 17.1 months; HR: 0.30; 95% CI: 0.08–1.14; <i>P</i> = 0.078), TMB < 10 had less favorable TTNT (median 2.8 vs. 6.5 months; HR: 2.36; 95% CI: 1.25–4.45; <i>P</i> = 0.008) and OS (median 4.5 vs. 13.1 months; HR: 1.82, 95% CI: 0.87–3.81; <i>P</i> = 0.11). TMB ≥ 10 robustly identifies patients with mEG with more favorable outcomes on 2 L ICPI monotherapy versus chemotherapy. 1 L data are more limited, but effects are consistent with 2L.</p>Significance:<p>Using real-world data, we sought to evaluate robustness of these clinical associations using the same assay platform and biomarker cut-off point used in both clinical trials and pan-tumor CDx approvals for later treatment lines. TMB ≥ 10 robustly identified patients with mEG with more favorable outcomes on ICPI monotherapy versus chemotherapy and suggests this subset of patients could be targeted for further trial development.</p></div>" @default.
- W4362548596 created "2023-04-06" @default.
- W4362548596 creator A5025819053 @default.
- W4362548596 creator A5045665778 @default.
- W4362548596 creator A5047258840 @default.
- W4362548596 creator A5052504293 @default.
- W4362548596 creator A5060537297 @default.
- W4362548596 creator A5062019987 @default.
- W4362548596 creator A5071611972 @default.
- W4362548596 creator A5088559019 @default.
- W4362548596 date "2023-04-04" @default.
- W4362548596 modified "2023-09-24" @default.
- W4362548596 title "Data from Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal Cancer" @default.
- W4362548596 doi "https://doi.org/10.1158/2767-9764.c.6551036" @default.
- W4362548596 hasPublicationYear "2023" @default.
- W4362548596 type Work @default.
- W4362548596 citedByCount "0" @default.
- W4362548596 crossrefType "posted-content" @default.
- W4362548596 hasAuthorship W4362548596A5025819053 @default.
- W4362548596 hasAuthorship W4362548596A5045665778 @default.
- W4362548596 hasAuthorship W4362548596A5047258840 @default.
- W4362548596 hasAuthorship W4362548596A5052504293 @default.
- W4362548596 hasAuthorship W4362548596A5060537297 @default.
- W4362548596 hasAuthorship W4362548596A5062019987 @default.
- W4362548596 hasAuthorship W4362548596A5071611972 @default.
- W4362548596 hasAuthorship W4362548596A5088559019 @default.
- W4362548596 hasBestOaLocation W43625485962 @default.
- W4362548596 hasConcept C104317684 @default.
- W4362548596 hasConcept C121608353 @default.
- W4362548596 hasConcept C126322002 @default.
- W4362548596 hasConcept C143998085 @default.
- W4362548596 hasConcept C180754005 @default.
- W4362548596 hasConcept C185592680 @default.
- W4362548596 hasConcept C2776694085 @default.
- W4362548596 hasConcept C2779767149 @default.
- W4362548596 hasConcept C44249647 @default.
- W4362548596 hasConcept C55493867 @default.
- W4362548596 hasConcept C61320498 @default.
- W4362548596 hasConcept C71924100 @default.
- W4362548596 hasConcept C90924648 @default.
- W4362548596 hasConceptScore W4362548596C104317684 @default.
- W4362548596 hasConceptScore W4362548596C121608353 @default.
- W4362548596 hasConceptScore W4362548596C126322002 @default.
- W4362548596 hasConceptScore W4362548596C143998085 @default.
- W4362548596 hasConceptScore W4362548596C180754005 @default.
- W4362548596 hasConceptScore W4362548596C185592680 @default.
- W4362548596 hasConceptScore W4362548596C2776694085 @default.
- W4362548596 hasConceptScore W4362548596C2779767149 @default.
- W4362548596 hasConceptScore W4362548596C44249647 @default.
- W4362548596 hasConceptScore W4362548596C55493867 @default.
- W4362548596 hasConceptScore W4362548596C61320498 @default.
- W4362548596 hasConceptScore W4362548596C71924100 @default.
- W4362548596 hasConceptScore W4362548596C90924648 @default.
- W4362548596 hasLocation W43625485961 @default.
- W4362548596 hasLocation W43625485962 @default.
- W4362548596 hasOpenAccess W4362548596 @default.
- W4362548596 hasPrimaryLocation W43625485961 @default.
- W4362548596 hasRelatedWork W1989767122 @default.
- W4362548596 hasRelatedWork W2008153433 @default.
- W4362548596 hasRelatedWork W2097014703 @default.
- W4362548596 hasRelatedWork W21362182 @default.
- W4362548596 hasRelatedWork W2149402148 @default.
- W4362548596 hasRelatedWork W2370772550 @default.
- W4362548596 hasRelatedWork W2885637573 @default.
- W4362548596 hasRelatedWork W3120340770 @default.
- W4362548596 hasRelatedWork W3207036495 @default.
- W4362548596 hasRelatedWork W4254054468 @default.
- W4362548596 isParatext "false" @default.
- W4362548596 isRetracted "false" @default.
- W4362548596 workType "article" @default.